Is erdafitinib included in medical insurance? How much does it cost?

Erdafitinib (erdafitinib) is an oral tyrosine kinase inhibitor that specifically targets fibroblast growth factor receptor (FGFR). It is mainly used to treat locally advanced or metastatic urothelial cancer, especially patients carrying FGFR2 or FGFR3 gene mutations. This drug offers a new treatment option for patients whose disease has progressed despite platinum-based chemotherapy.

Erdafitinib can effectively control the growth and spread of tumor cells by inhibiting the activity ofFGFR, thereby prolonging the survival period and improving the quality of life of patients. Relevant research data show that a considerable number of patients treated with erdafitinib achieved partial or complete tumor shrinkage.

However, the use of erdafitinib is also associated with some side effects, such as hyperphosphatemia, stomatitis, nausea, etc., which require close monitoring and adjustment of the treatment plan.

Erdafitinib has not yet entered the domestic market, so there is no way to include it in domestic medical insurance reimbursement items. Therefore, patients need to go overseas to purchase it or contact a formal overseas medical consulting company to obtain it. It is understood that the original drug specification of erdafitinib in Hong Kong is 4mg*14 tablets, and the price is as high as more than 20,000 yuan. At the same time, there are also generic drugs of erdafitinib on the market. For example, the version marketed overseas in Bangladesh is available in three specifications: 3mg, 4mg, and 5mg. The price of 28 tablets of 4mg is about 1,000 yuan. For more information about generic drugs of erdafitinib, patients can consult professional overseas medical consulting companies.

In general, erdafitinib, with its mechanism of action and therapeutic effect, has shown good potential in the treatment of urothelial cancer and brought new hope to patients. In the future, with the deepening of research and the expansion of clinical application, erdafitinib is expected to bring good news to more patients.